Biogen forges on with Alzheimer’s therapy development despite Phase II miss

Biogen and Ionis' anti-tau therapy demonstrated the strongest efficacy signal at the low 60mg Q6M dose in Alzheimer's disease. The anti-tau therapy demonstrated the strongest efficacy signal at the low 60mg Q6M dose. Biogen will progress diranersen to a Phase III trial in Alzheimer’s disease. Credit: Jeviredurose_design / Shutterstock.com. Biogen is firing up a registrational programme for its tau-focused Alzheimer’s disease therapy, diranersen, despite the drug missing its primary endpoint in a mid-stage study. During the ongoing Phase II CELIA trial (NCT05399888), which is exploring the efficacy and safety of the first-in-class antisense oligonucleotide (ASO) in patients with mild cognitive…

Source: Clinical Trials Arena